Back

Risk stratification of adverse events in patients with coronary artery disease with type 2 diabetes with preserved ejection fraction

13 May 2024 (09:00 - 10:20)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - pathophysiology and mechanisms 5 Heart Failure with Preserved Ejection Fraction (HFpEF) HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Shakhnoza Mukhtarova

Tashkent Pediatric Medical Institute, Tashkent (Uzbekistan)

5 More presentations in this session

Presentation thumbnail
Analysis of the use of incretins in patients with coronary artery disease with DM 2 with preserved ejection fraction.
Doctor S. Mukhtarova (Tashkent, UZ)
Abstract Slides Video
Presentation thumbnail
Impact of HFpEF in pacemaker patients: a closer look at heart failure events and mortality risk
Mrs E. Santos (Vila Nova de Gaia, PT)
Abstract Slides Video
Presentation thumbnail
Unraveling gender's influence: a detailed analysis of mortality and acute heart failure risk in HFpEF Patients post-pacemaker Implantation
Miss E. Santos (Vila Nova de Gaia, PT)
Abstract Slides Video
Presentation thumbnail
Cardiopulmonary exercise testing in HFpEF patients - a stress-to-rest ratio analyses
Doctor K. Franz (Berlin, DE)
Abstract Slides Video
Presentation thumbnail
Usefulness of the H2PEF score in the stratification of patients with a diagnosis of heart failure with preserved ejection fraction in primary care
Miss V. Cendros (ES)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in chronic heart failure - pathophysiology and mechanisms 5

The Event

Event poster

Heart Failure 2024

13 May 2024 09:00 CET
You may be interested in
thumbnail
Congress Presentation
Role of mitral regurgitation in a new predictive model for mortality and hospitalization risk in heart failure
thumbnail
Congress Session
Broadening phenotype of diabetic heart disease
thumbnail
Congress Presentation
Novel support tool for predicting incident heart failure in type-2 diabetes mellitus: a precision medicine approach

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources